Mammotome secures CE mark for HydroMARK Plus, expanding breast biopsy marker access in Europe.

Mammotome, a Danaher company, has received the CE mark for its HydroMARK™ Plus Breast Biopsy Site Marker. This approval allows wider access to the innovative marker technology across Europe, benefiting patients undergoing breast cancer diagnosis and treatment. The HydroMARK Plus combines proprietary hydrogel technology with features that enhance marker stability and visibility in breast care, supporting improved clinical outcomes.